Global Cell-based Assays (Reagents & Assay Kits, Cell lines, Plate Readers, HCS, HTS, Software & Assay Development Services) Market - Forecast to 2018

DUBLIN, July 16, 2014 /PRNewswire/ -- Research and Markets(http://www.researchandmarkets.com/research/txb2vj/cellbased_assays) has announced the addition of the "Cell-based Assays Market by Product, Application & End-user - Global Forecast to 2018" report to their offering.

http://photos.prnewswire.com/prnh/20130307/600769

The market for cell-based assays is driven by the preference over biochemical assays and animal models and the emergent 3D cell-based assay techniques in cell-based assays.

There has been a substantial rise in the costs to develop a new drug in recent years. This is specially observed when a new compound enters animal testing. The use of animals in experimentation is becoming dearer, due to limitations such as high costs involved in breeding and acquisition of animals, due to the complexity of procedures involved in the in vivo testing, and several other ethical issues and legal issues associated with it. Moreover the traditional biochemical assays also posses many limitations. To counteract these issues there has been a paradigm shift towards the use of cell-based assays.

The consumables formed the largest product segment of the total cell-based assays market in 2013, which includes assay kits and reagents, microplates and cell lines. The largest contribution of consumables was attributed to the large volume market of reagents and assay kits; where most of the innovation is taking place.

Drug discovery was the most prominent application of cell-based assays. Within drug discovery, lead identification and optimization accounted for the largest share in 2013. With respect to end users, the pharmaceutical and biotechnology companies commanded the largest share in 2013. These industries are focusing on screening extensive libraries of compounds that could become leads for potential drug candidates. The screening process has helped the pharmaceutical companies to run more cost and time efficient methods.

For accurate results, the low cost label-free technology in cell based assays has emerged as a momentous technology that has been driving the growth of cell-based assay market. With the advancement in the cell stem cell culture, induced pluripotent stem cells will be emerging in near future. With the increasing demand of emergent 3D cell-based assay, it is estimated to be the fastest growing technology in the next five years.

North America accounted for the largest share of the global cell-based assay market in 2013. The presence of a large number of market players along with government funding for drug discovery and increasing number of public-private partnerships are the factors driving the North American cell-based assay market.

Key Topics Covered:

1 Introduction

2 Executive Summary

3 Premium Insights

4 Market Overview

5 Cell-Based Assays Market, By Product

6 Cell-Based Assays Market, By Application

7 Cell-Based Assays Market, By End User

8 Cell-Based Assays, By Geography

9 Competitive Landscape

10 Company Profiles

Companies Mentioned:

• Becton, Dickinson and Company
• Cell Signaling Technology
• Cisbio Bioassays (Argos Soditic)
• Danaher Corporation
• Discoverx
• EMD Millipore (A Subsidiary of Merck Kgaa)
• Ge Healthcare (Subsidiary of General Electric Company)
• Life Technologies (Thermo Fisher Scientific)
• Perkinelmer, Inc.
• Promega Corporation

For more information visit http://www.researchandmarkets.com/research/txb2vj/cellbased_assays

Media Contact: Laura Wood, +353-1-481-1716, press@researchandmarkets.net